Ipamorelin side effects: what the literature reports
The cleanest GHRP profile in the literature is not the same as no profile.
TL;DR
- Ipamorelin is among the cleanest GHRPs (in plain English: small molecules that signal the pituitary to release growth hormone).
- The most common reported effects are injection-site reactions, transient flushing, mild headache, and temporary hunger.
- Compounded ipamorelin is not FDA-approved. Side-effect tracking is a clinician’s job, not a self-managed checklist.
What it is
Ipamorelin is a synthetic GHRP (growth hormone-releasing peptide) developed in the late 1990s. Its appeal in the literature is what it does not do: it triggers a growth hormone pulse without meaningfully raising cortisol or prolactin in healthy-adult dose ranges (Raun et al., Eur J Endocrinol, 1998).
How it works
Picture a doorbell with five buttons. Older GHRPs press the growth hormone button — and accidentally lean on the cortisol and prolactin buttons too. Ipamorelin presses just the one button. That selectivity, demonstrated in animal and early human pharmacology, is the reason it shows up in modern clinician protocols (Gobburu et al., Clin Pharmacokinet, 2004).
Who asks about it
People usually ask about side effects after reading marketing copy that calls ipamorelin “side-effect free.” It is not. It is cleaner, in the sense that the unwanted bell presses are quieter. That is a real advantage. It is not the same as zero risk.
What the research says
In dose-finding studies in healthy adults, the most common observations were injection-site irritation, transient flushing, lightheadedness during the first hour after injection, and a temporary increase in appetite (consistent with growth hormone secretagogue activity). Headache and mild fatigue have been reported. Cortisol and prolactin elevations seen with GHRP-6 and GHRP-2 are largely absent at studied ipamorelin doses (Raun et al., 1998). Long-term human data is limited.
What to know before considering it
Ipamorelin is not appropriate for people with active cancer, certain pituitary conditions, or untreated retinopathy. Anyone on insulin or diabetes medication should be monitored — growth hormone activity can shift insulin sensitivity. Compounded ipamorelin is not FDA-approved. Side-effect monitoring should happen alongside a licensed clinician.
The Halftime POV
A compound being “clean” in the literature is not a green light. It is a starting point. The honest move is to begin low, monitor labs and lived response together, and treat any unusual symptom — even a mild one — as worth a clinician conversation.
Related reading:
- Ipamorelin: what this GHRP peptide is
- Ipamorelin research: published evidence reviewed
- CJC-1295 + Ipamorelin: why they are often combined
FAQ
Q: What are the most common ipamorelin side effects? A: Published trials and case reports describe injection-site reactions, mild headache, transient flushing, lightheadedness, and a temporary increase in hunger. Most reactions are short-lived. Effects on cortisol and prolactin in the studied dose ranges are minimal compared with older GHRPs.
Q: Does ipamorelin raise cortisol? A: Compared with earlier GHRPs (GHRP-2 and GHRP-6), ipamorelin shows little to no effect on cortisol or prolactin in healthy-adult dosing studies. This is one reason clinicians often select it over those older compounds.
Q: Is ipamorelin FDA-approved? A: No. Ipamorelin is not FDA-approved as a finished drug product. Compounded ipamorelin is prepared by state-licensed 503A pharmacies and is not FDA-approved. Any use requires a licensed clinician’s evaluation.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin. Clinical Pharmacokinetics, 2004.
